Description: Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Home Page: www.imagobio.com
IMGO Technical Analysis
329 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
415 529 5055
Officers
| Name | Title |
|---|---|
| Dr. Hugh Young Rienhoff Jr., M.D. | CEO & Director |
| Ms. Laura G. Eichorn | Chief Financial Officer |
| Mr. Michael H. Arenberg J.D., M.B.A. | Chief Operating & Bus. Officer |
| Ms. Hsiangyi Chiang | Sr. VP of Fin. & Principal Accounting Officer |
| Dr. Amy E. Tapper Ph.D. | Chief of Technical Operations |
| Ms. Jennifer Peppe | Global Head of Clinical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.042 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-07-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |